Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Taymeyah E Al-ToubahBrian MorseJonathan R StrosbergPublished in: The oncologist (2019)
Patients with advanced lung neuroendocrine neoplasms have very few systemic treatment options. The capecitabine and temozolomide regimen has previously shown significant activity in patients with pancreatic neuroendocrine tumors (NETs) but has not been explored in metastatic lung NETs. This study showed that this regimen is associated with a high response rate (30%) and a relatively tolerable toxicity profile in this population.